Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Laboratories, BAC – the Bio Affinity Company

Bio-Rad Laboratories this week said that it will launch later this year the ProteOn Manager 2.1 Security Edition Software and the ProteOn XPR36 Installation Qualification and Operation Qualification Kit. Both are regulatory tools for the ProteOn XPR36 Protein Interaction Array System.
The ProteOn Manager 2.1 software is designed to help customers in drug development meet the requirements for 21 CFR part II “by providing functionality for maintaining data security, data integrity, auditing, and the traceability of electronic records,” the company said in a statement.
The ProteOn XPR36 Installation kit is for validating and recording instrument performance by drug discovery and development researchers. The kit includes control reagents, fully automated software, and reporting functions.

BAC – the Bio Affinity Company launched this week the Capture Select IgA and IgM affinity matrices for the purification of IgA and IgM.
CaptureSelect IgA contains an affinity ligand that binds to a unique domain present on all subclasses of IgA while offering no cross-reactivity with IgM or IgG. CaptureSelect IgM contains an affinity ligand directed toward a unique domain present on both human and mouse IgM antibodies and offers no cross-reactivity with human or mouse IgA or IgM

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.